Lixte Biotechnology Holdings, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 1.37 million compared to USD 1.66 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 1.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.429 USD | +1.63% | -1.28% | +3.36% |
05-09 | Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-23 | Lixte Biotechnology Files Up to $50 Million Mixed Shelf | MT |
1st Jan change | Capi. | |
---|---|---|
+3.36% | 5.38M | |
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023